Jul. 10 at 2:40 PM
$ACOG AI response: Alpha Cognition's sales revenue is beginning to increase, but it's important to understand the context:
Alpha Cognition recently launched its primary product, ZUNVEYL, in the US market on March 17, 2025.
In the first quarter of 2025, the company reported a net product revenue of
$347 thousand from ZUNVEYL sales. This is a significant increase from zero product revenue in the same period a year ago.
Additionally, the company secured
$2.6 million in licensing revenue during Q1 2025.
Future projections
Analysts are forecasting significant revenue growth for Alpha Cognition in the coming years. According to one source, the consensus revenue forecast for 2025 is
$221.15 million, rising to
$552.60 million in 2026 and
$1.47 billion in 2027.
This projected growth is based on the expectation that ZUNVEYL, with its benefits in treating Alzheimer's disease, will gain traction in the market.
